title: Circulating omentin as a novel biomarker of endothelial dysfunction.
abstract: Omentin is a novel soluble lectin expressed mainly in the stromal-vascular cells from visceral adipose tissue with vasodilator effect in isolated blood vessels. To gain insight in the relationship between obesity and cardiovascular risk factors, we aimed to explore the interaction among circulating omentin, metabolic parameters, and endothelial function. Circulating omentin (enzyme-linked immunosorbent assay) was studied in 248 white men (148 with normal glucose tolerance (NGT) and 100 with impaired glucose tolerance (IGT)). Insulin sensitivity was measured using the frequently sampled intravenous glucose tolerance test. Vascular reactivity was measured by high-resolution ultrasound of the brachial artery. Circulating omentin concentration was significantly increased in lean compared with overweight and obese subjects (53.7 ± 16.9 vs. 45.2 ± 16.8 and vs. 40.1 ± 15.5 ng/ml, P < 0.0001). Circulating omentin concentration correlated with age, BMI, waist-to-hip ratio (WHR), percentage of fat mass, systolic and diastolic blood pressure, endothelium-dependent and independent vasodilation (EDV and EIV), C-reactive protein, and interleukin-6 (IL-6). In IGT subjects, circulating omentin concentration also correlated with insulin sensitivity, although this association did not remain significant after controlling for BMI. In a multiple linear regression analysis, circulating omentin concentration (P = 0.01), systolic blood pressure (P = 0.04), and BMI (P = 0.04) contributed independently to EDV after controlling for age and C-reactive protein in IGT subjects. In NGT subjects, only circulating omentin concentration (P = 0.01) was significantly associated with EDV. In conclusion, circulating omentin concentration could be a useful marker of endothelial function.
authors.affiliation: Department of Diabetes, Endocrinology and Nutrition. Institut d'Investigació Biomédica de Girona, CIBER Fisiopatología de la Obesidad y Nutrición CB06/03/010, Girona, Spain.
authors.forename: José Maria
authors.initials: JM
authors.lastname: Moreno-Navarrete
authors.forename: Francisco
authors.initials: F
authors.lastname: Ortega
authors.forename: Antoni
authors.initials: A
authors.lastname: Castro
authors.forename: Mónica
authors.initials: M
authors.lastname: Sabater
authors.forename: Wifredo
authors.initials: W
authors.lastname: Ricart
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Fernández-Real
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D001823:Body Composition; D015992:Body Mass Index; D001916:Brachial Artery / Q000000981:diagnostic imaging; D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000097:blood*; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000503:physiopathology*; D004797:Enzyme-Linked Immunosorbent Assay; D058851:GPI-Linked Proteins / Q000097:blood; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications*; D005951:Glucose Tolerance Test; D006801:Humans; D007333:Insulin Resistance; D015848:Interleukin-5 / Q000378:metabolism; D037102:Lectins / Q000097:blood*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000503:physiopathology*; D050177:Overweight / Q000097:blood; D012016:Reference Values; D012307:Risk Factors; D013851:Thinness / Q000097:blood; D014463:Ultrasonography; D014652:Vascular Diseases / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D014664:Vasodilation; D049629:Waist-Hip Ratio; D044465:White People
chemical_list: D015415:Biomarkers; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D015848:Interleukin-5; D037102:Lectins; D002097:C-Reactive Protein